CAR-T cell therapy has transformed treatment for certain cancers by engineering a patient’s immune cells to identify and ...

CREATE Medicines, Inc. ("CREATE"), a clinical-stage biotechnology company pioneering in vivo immune cell programming, today ...

This Collection provides updated research from the Immune cell engineering for cancer therapy 2024 Collection. Chimeric antigen receptor (CAR) T cell therapies have revolutionized the treatment of ...

Scientists have built functional cancer-fighting immune cells directly inside living animals, skipping the expensive and time-consuming process of extracting a patient’s cells and engineering them in ...

Chimeric antigen receptor T cell (CAR-T) therapies have revolutionized treatment for various blood cancers. When traditional treatments fail, CAR-T therapies provide a second highly effective option.

Efficient T-cell engineering is crucial for the success of CAR T-cell therapy research, but it requires multiple labor-intensive steps, including T-cell isolation, activation, and transduction.

Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell therapy, or CAR-T cell therapy. Over time, the engineered immune ...

For the first time, researchers at the University of British Columbia have demonstrated how to reliably produce an important type of human immune cell—known as helper T cells—from stem cells in a ...

Promising advancements in CAR T-cell therapy for large B-cell lymphoma (LBCL) include potential new safety parameters, opportunities for precision care, and increased chances of achieving remission ...

All-RNA gene writing for T cells (RetroT): Utilizes human LINE-1 machinery to drive programmable, site-specific integration of multi-kb payloads, without DSBs, supporting a superior genomic safety ...